login
  Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Implantable cardioverter defibrillators in patients nearing the end of life


Monday, 23 Apr 2012 14:02
Rachel Lampert
Rachel Lampert


Rachel Lampert, associate professor of Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, USA, is giving the talk “When to consider ICD deactivation: End-of-life issues” at Heart Rhythm 2012 (9–12 May 2012, Boston, USA). She talked to Cardiac Rhythm News about this topic.


When would you consider deactivating an implantable cardioverter defibrillator (ICD) in a patient who was nearing the end of their life?

The short answer is that ICD deactivation should be considered whenever a patient wants it to be considered. Even if a patient was not near the end of their life, legally and ethically, an ICD should be deactivated if the patient wants it to be deactivated.

However, the longer answer is that all patients with an ICD should have an opportunity to discuss the option of deactivation before they reach the end of their life (ie, shortly after implantation). The issue of deactivation should also be proactively discussed with a patient when their condition worsens and a good time to discuss the issue is when other preferences, such advanced directives [living wills] or a do not resuscitate (DNR) orders, are being discussed. It is not up to the physician when an ICD “should” be deactivated. The role of the physician is to make sure the patient understands the consequences of keeping it active versus deactivating it—when the patient has all of the available facts, then the decision to deactivate is up to them. The decision should be made in the context of the person’s overall goals for his or her care at that time.


What are the indications that a patient is nearing the end of their life?


Often it is not clear, and this is one of the difficult issues in discussing deactivation and one of the reasons it is so important to discuss the issue early on. Other times, though, physicians can tell as a patient’s disease course progresses (whether it is their underlying heart disease or another disease such as cancer) that the disease is overcoming the patient and therapeutic options are exhausted.


You state that a good time to discuss deactivation is when advance healthcare directives are being discussed. Would you therefore encourage patients to include their wishes on ICD deactivation in these documents and generally why in your view are such directives important?


I would definitely encourage patients to write an advanced directive, and that they include their wishes regarding ICD deactivation. This is important, as is all advanced planning relating to ICD deactivation at the end of life, to avoid potential shocks, which are painful, as a person is dying.


If a healthcare provider has ethical or moral concerns about deactivation, what should they do?


The American Medical Association (AMA) code of ethics states that a physician should not be compelled to perform an action that goes against his moral beliefs. However, our document (1) stresses that the healthcare provider should not attempt to impose his beliefs on the patient and should help direct the patient to an alternate provider who can help him.


References

1. Lampert et al. Heart Rhythm Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing the end of life or requesting withdrawal of therapy. Heart Rhythm 2010; 7:1008–26




Add New Comment

Most popular


Medtronic completes acquisition of Covidien
Tuesday, 27 Jan 2015
Under the terms of the acquisition agreement, Medtronic Inc and Covidien plc are now combined under Medtronic plc. Medtronic completes acquisition of Covidien

Thursday, 26 Feb 2015
Vitaria delivers autonomic regulation therapy for patients who have moderate to severe heart failure with left ventricular dysfunction (ejection fraction < 40%), and who remain symptomatic despite ... Vitaria vagal nerve stimulation system receives CE mark for treatment of chronic heart failure

Bridging during anticoagulation interruption associated with higher bleeding risk in AF patients
Friday, 30 Jan 2015
A subanalysis from the ORBIT-AF registry has found that atrial fibrillation patients who receive bridging anticoagulation therapy during anticoagulation interruption are at higher risk of bleeding ... Bridging during anticoagulation interruption associated with higher bleeding risk in AF patients

Features


SERVE-HF could be a wake-up call for cardiologists about central sleep apnoea
Tuesday, 24 Mar 2015
Martin Cowie (Imperial College London, London, UK) is the principal investigator of the SERVE-HF study, which is assessing the use of adaptive servo-ventilation (PaceWave, ResMed) in chronic heart ... SERVE-HF could be a wake-up call for cardiologists about central sleep apnoea

ENSURE-AF: Largest trial ever to explore novel oral anticoagulation in AF patients undergoing cardioversion
Tuesday, 10 Feb 2015
Andreas Goette explains the rationale and details of the ENSURE-AF trial, the largest prospective study evaluating the efficacy and safety of edoxaban (Daiichi Sankyo) compared with enoxaparin/... ENSURE-AF: Largest trial ever to explore novel oral anticoagulation in AF patients undergoing cardioversion

Profiles


Hung-Fat Tse
Tuesday, 03 Feb 2015
While Hung-Fat Tse’s initial research interests focused on device therapy for cardiac arrhythmias, ... Hung-Fat Tse

Massimo Santini
Friday, 10 Oct 2014
Massimo Santini performed the first fulguration of the atrioventricular node of resistant ... Massimo Santini

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions